PUBLIC COMPANY
save$BMYBRISTOL MYERS SQUIBB CO
$BMY61.15+0.53%Princeton, NJ, USupdated 1d ago
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multip read more
…
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval166 co-mentions · 83 sources
- drugOPDIVO166 co-mentions · 83 sources
- drugOPDIVO QVANTIG166 co-mentions · 83 sources
- drugnivolumab166 co-mentions · 83 sources
- company$CELG-RIBRISTOL MYERS SQUIBB CO84 co-mentions · 84 sources
- tagDrug Shortage1 co-mentions · 1 sources
- drugazacitidine1 co-mentions · 1 sources
- drugOnureg1 co-mentions · 1 sources
pipeline
3
marketed
0
phase 3
0
catalysts ytd
6
approvals ytd
2
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Unknown
drug
INREBIC
1 INDICATIONS AND USAGE INREBIC ® is indicated for the tr…
Tyrosine-protein kinase JAK2Receptor-type tyrosine-protein kinase FLT3
drugOPDIVO
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
drugOPDIVO QVANTIG
1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination o…
Programmed cell death protein 1
Upcoming
Recent(90d)
earnings (1)
🐶 Hiring Signal
next earnings Oct 29, 2026
Where BRISTOL MYERS SQUIBB CO is staffing up — a leading indicator of pipeline and commercial priorities.
News
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 2d ago
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Novartis wagers almost $8B on a Chinese biotech’s RNA drugsIn exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.biopharma_dive · 2d ago
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 3d ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 3d ago
- Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshakenThe revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has raised concerns ahead of the study’s readout, but analysts were quick to di…fiercebiotech · 3d ago
- Patient death raises liver questions ahead of Bristol Myers readoutA patient’s death is raising safety questions ahead of an upcoming readout for Bristol Myers Squibb’s lung disease candidate. Bristol Myers disclosed one case of fatal liver injury in a May amendme…endpoints · 4d ago
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsA spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the…biopharma_dive · 4d ago
- $40M in tax incentives expected to generate 1,600+ life sciences jobs in MassachusettsOf the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are each expected to gain over 200 jobs. Tax incentive award recipients include…biospace · 4d ago
- Biopharma needs to reward scientists' judgmentIt’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.biospace · 4d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that